Lilly's diabetes pill beats Novo's Rybelsus in head-to-head trial, company mulls fast-track filing

Eli Lilly said Wednesday that orforglipron beat Novo Nordisk’s oral drug Rybelsus in a head-to-head trial in diabetes patients, the latest twist in the Indianapolis drugmaker's efforts to get its obesity pill to market. ...